BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, Yang MJ, Lim SG, Kim S, Cheong JY, Cho SW. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis 2018;50:370-7. [PMID: 29398414 DOI: 10.1016/j.dld.2017.12.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Xie Q, Lu S, Kuang M, He S, Yu C, Hu C, Zou Y. Assessing the longitudinal association between the GGT/HDL-C ratio and NAFLD: a cohort study in a non-obese Chinese population. BMC Gastroenterol 2022;22:500. [PMID: 36471271 DOI: 10.1186/s12876-022-02598-y] [Reference Citation Analysis]
2 Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Wan ZH, Tang NSY, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022;20:2809-2817.e28. [PMID: 34890795 DOI: 10.1016/j.cgh.2021.12.002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 66.0] [Reference Citation Analysis]
3 Cozzolino R, De Giulio B, Martignetti A, Forte G, Dallio M, Romeo M, Scognamiglio F, Ventriglia L, Stocchero M, Federico A. Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence. Metabolomics 2022;18:98. [PMID: 36441279 DOI: 10.1007/s11306-022-01960-1] [Reference Citation Analysis]
4 Wang X, Han Y, Liu Y, Hu H. Association between serum uric acid-to-creatinine ratio and non-alcoholic fatty liver disease: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02500-w] [Reference Citation Analysis]
5 Li K, Li J, Cheng X, Wang J, Li J. Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants. Front Endocrinol 2022;13:969783. [DOI: 10.3389/fendo.2022.969783] [Reference Citation Analysis]
6 Tang A, Ng CH, Phang PH, Chan KE, Chin YH, Fu CE, Zeng RW, Xiao J, Tan DJH, Quek J, Lim WH, Mak LY, Wang JW, Chew NWS, Syn N, Huang DQ, Siddiqui MS, Sanyal A, Muthiah M, Noureddin M. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00669-3. [PMID: 35863685 DOI: 10.1016/j.cgh.2022.06.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
7 Tang Y, Wei ZM, Li N, Sun LL, Jin ZY, Wu Z, Sun H. Quantitative analysis of the risk of type 2 diabetes and fatty liver in non-obese individuals by computed tomography. Abdom Radiol (NY) 2022;47:2099-105. [PMID: 35389075 DOI: 10.1007/s00261-022-03506-4] [Reference Citation Analysis]
8 Ciardullo S, Grassi G, Mancia G, Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2022;34:365-71. [PMID: 34678858 DOI: 10.1097/MEG.0000000000002299] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
9 Hu C, Zhuang X, Zhang J, Wang T, Du S, Wang J, Peng X, Cao Q, Zhang M, Jiang Y. Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. Lab Med 2022:lmab118. [PMID: 35075477 DOI: 10.1093/labmed/lmab118] [Reference Citation Analysis]
10 Wu W, Xiang J, Chen X. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:773342. [PMID: 34992579 DOI: 10.3389/fendo.2021.773342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Liebe R, Krawczyk M. Schlanke Patienten. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_29] [Reference Citation Analysis]
12 Kitazawa A, Maeda S, Fukuda Y. Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data. PLoS One 2021;16:e0257352. [PMID: 34543321 DOI: 10.1371/journal.pone.0257352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Chung GE, Cho EJ, Yoon JW, Yoo JJ, Chang Y, Cho Y, Park SH, Han K, Shin DW, Yu SJ. Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea. Metabolism 2021;123:154866. [PMID: 34411553 DOI: 10.1016/j.metabol.2021.154866] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
14 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
15 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
16 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
17 Imamura Y, Mawatari S, Oda K, Kumagai K, Hiramine Y, Saishoji A, Kakihara A, Nakahara M, Oku M, Hosoyamada K, Kanmura S, Moriuchi A, Miyahara H, Akio Ido. Changes in body composition and low blood urea nitrogen level related to an increase in the prevalence of fatty liver over 20 years: A cross-sectional study. Hepatol Res 2021;51:570-9. [PMID: 33675676 DOI: 10.1111/hepr.13631] [Reference Citation Analysis]
18 Castro-sánchez S, Pérez-giraldo E, Restrepo-gutiérrez JC, Builes-montaño CE. Enfermedad hepática grasa no alcohólica en personas no obesas: revisión narrativa de la literatura. Hepatología 2021. [DOI: 10.52784/27112330.129] [Reference Citation Analysis]
19 Zhang Q, Ma X, Xing J, Shi H, Yang R, Jiao Y, Chen S, Wu S, Zhang S, Sun X. Serum Uric Acid Is a Mediator of the Association Between Obesity and Incident Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. Front Endocrinol (Lausanne) 2021;12:657856. [PMID: 34054728 DOI: 10.3389/fendo.2021.657856] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
20 Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis 2020;19:245. [PMID: 33239040 DOI: 10.1186/s12944-020-01419-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
21 Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. World J Gastroenterol 2020; 26(42): 6514-6528 [PMID: 33268944 DOI: 10.3748/wjg.v26.i42.6514] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
22 Haidari F, Hojhabrimanesh A, Helli B, Seyedian SS, Ahmadi-Angali K, Abiri B. A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial. BMC Gastroenterol 2020;20:349. [PMID: 33081717 DOI: 10.1186/s12876-020-01502-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
24 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 21.0] [Reference Citation Analysis]
25 Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739-52. [PMID: 32413340 DOI: 10.1016/S2468-1253(20)30077-7] [Cited by in Crossref: 289] [Cited by in F6Publishing: 239] [Article Influence: 96.3] [Reference Citation Analysis]
26 Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis 2020;21:372-84. [PMID: 32369237 DOI: 10.1111/1751-2980.12871] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
27 Wei F, Li J, Chen C, Zhang K, Cao L, Wang X, Ma J, Feng S, Li WD. Higher Serum Uric Acid Level Predicts Non-alcoholic Fatty Liver Disease: A 4-Year Prospective Cohort Study. Front Endocrinol (Lausanne) 2020;11:179. [PMID: 32328031 DOI: 10.3389/fendo.2020.00179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Shi Y, Wang Q, Sun Y, Zhao X, Kong Y, Ou X, Jia J, Wu S, You H. The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2020;54:378-87. [PMID: 31651571 DOI: 10.1097/MCG.0000000000001270] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
29 Zhang YN, Wang QQ, Chen YS, Shen C, Xu CF. Association between Serum Uric Acid to HDL-Cholesterol Ratio and Nonalcoholic Fatty Liver Disease in Lean Chinese Adults. Int J Endocrinol 2020;2020:5953461. [PMID: 32273892 DOI: 10.1155/2020/5953461] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
30 Molina-Molina E, Krawczyk M, Stachowska E, Lammert F, Portincasa P. Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment. Clin Res Hepatol Gastroenterol 2019;43:638-45. [PMID: 31196707 DOI: 10.1016/j.clinre.2019.04.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
31 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
32 Wang L. Ultrasound-Diagnosed Nonalcoholic Fatty Liver Disease Independently Predicts a Higher Risk of Developing Diabetes Mellitus in Nonoverweight Individuals. Acad Radiol 2019;26:863-8. [PMID: 30254005 DOI: 10.1016/j.acra.2018.08.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
33 Cho HJ, Hwang S, Park JI, Yang MJ, Hwang JC, Yoo BM, Lee KM, Shin SJ, Lee KJ, Kim JH, Cheong JY, Cho SW, Kim SS. Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. Gut Liver 2019;13:440-9. [PMID: 30970431 DOI: 10.5009/gnl18382] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
34 Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol 2019;56:385-96. [PMID: 30519965 DOI: 10.1007/s00592-018-1266-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 14.3] [Reference Citation Analysis]
35 Shen X, Cai J, Gao J, Vaidya A, Liu X, Li W, Chen S, Zhou Y, Li Y, Zhang Y, Zhao J, Hu FB, Wu S, Gao X. Nonalcoholic Fatty Liver Disease and Risk of Diabetes: A Prospective Study in China. Endocr Pract 2018;24:823-32. [PMID: 29975579 DOI: 10.4158/EP-2018-0098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
36 Lonardo A, Targher G. From a fatty liver to a sugary blood. Dig Liver Dis 2018;50:378-80. [PMID: 29422241 DOI: 10.1016/j.dld.2018.01.126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]